My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Unicycive Therapeutics, Inc. - Common Stock (NQ:UNCY)

4.020 +0.280 (+7.49%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Unicycive Therapeutics, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Unicycive Shares Jump As Renazorb Achieves Primary Endpoint In Bioequivalence Study
 
Via Benzinga
Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom
Expects to dose patients in first-in-human Phase 1 study with UNI-494 in first quarter 2023 
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Unicycive Therapeutics, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
Via ACCESSWIRE
Unicycive Therapeutics' Geographic Atrophy Candidate Shows Improved Contrast Vision In Animal Studies
 
Via Benzinga
Unicycive Inks Licensing Pact For Its Kidney Disease Candidate In China
 
Via Benzinga
Planned Government Move To Expand Access To Drugs For End-Stage Renal Disease Patients Could Shine The Spotlight On Unicycive
In the U.S., reimbursement of dialysis expenses by the Centers for Medicare & Medicaid Services (CMS) is done using a prospective payment system (PPS) which enables the payout of a predetermined amount... 
Via Benzinga
Unicycive to Participate in Upcoming Investor Conferences
Highlights Late-Stage Program in Hyperphosphatemia and Early-Stage Program to Combat Diseases of Mitochondrial Dysfunction 
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Geographic Atrophy
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Unicycive Announces Third Quarter Financial Results and Provides Business Update
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Unicycive Completes Enrollment of Pivotal Bioequivalence Study for RENAZORB™ (lanthanum dioxycarbonate), an Investigational Treatment for Hyperphosphatemia in Chronic Kidney Disease (CKD) Patients on Dialysis
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers 
Via Benzinga
Unicycive to Showcase Pipeline of Innovative Product Candidates at American Society of Nephrology’s Kidney Week 2022
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells
You may remember learning that mitochondria are the powerhouse of the cells, but do you know the dangers that result if these cell superheroes get sick? 
Via TheNewswire.com
Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells
By David Willey, Benzinga 
Via News Direct
Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells
You may remember learning that mitochondria are the powerhouse of the cells, but do you know the dangers that result if these cell superheroes get sick?  
Via Benzinga
Unicycive Therapeutics to Present at Roth Inaugural Healthcare Opportunities Conference
Presentation to Highlight Late-Stage Program in Hyperphosphatemia and Early-Stage Program to Combat Diseases of Mitochondrial Dysfunction 
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication
Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States. 37 million American adults have CKD and more than 600,000... 
Via TheNewswire.com
How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication
Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States. 37 million American adults have CKD and more than 600,000... 
Via Benzinga
The Daily Biotech Pulse: Sesen Bio Stops Lead Assest Development In US, FDA Approves Eton Pharma's Partial Seizures Drug, Bavarian Nordic Inks Multiple Supply Pact For Monkeypox Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
CEO Clip Video Highlights How Unicycive Therapeutics is Working to Improve Quality of Life for Patients Suffering from Kidney Diseases
Vancouver, British Columbia--(Newsfile Corp. - June 29, 2022) - Business Television (BTV) chats with Shalabh Gupta, M.D., CEO of Unicycive... 
Via Newsfile
Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2022
Upgrades 
Via Benzinga
Traders News Source Interviews Dr. Shalabh Gupta, CEO at Unicycive Therapeutics, Inc.
NEW YORK, NY / ACCESSWIRE / May 24, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid cap publicly traded companies recently issued a... 
From Traders News Source
Via AccessWire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 1Life Healthcare (NASDAQ:ONEM) shares moved upwards by 22.4% to $9.58 during Wednesday's after-market session. The market value of their outstanding shares is at $1.8 billion. The company's, Q1... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Unicycive Therapeutics (NASDAQ:UNCY) shares moved upwards by 9.9% to $1.0 during Wednesday's after-market session. The company's market cap stands at $15.0 million. 
Via Benzinga
Glancy Prongay & Murray LLP Announces Investigation of Unicycive Therapeutics, Inc.
From Glancy Prongay & Murray LLP
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) stock moved upwards by 45.0% to $0.29 during Tuesday's pre-market session. The company's market cap stands at $8.5 million. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers TC BioPharm (Holdings) (NASDAQ:TCBP) shares rose 31.0% to $1.31 during Thursday's pre-market session. The company's market cap stands at $36.7 million.... 
Via Benzinga
22 Stocks Moving in Thursday's Pre-Market Session
Gainers TD Holdings, Inc. (NASDAQ: GLG) rose 81.2% to $0.43 in pre-market trading after the company reported FY21 results. Orphazyme A/S (NASDAQ: ORPH) shares rose 35.1% to $0.... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.